Indication · To treat relapsing forms of multiple sclerosis

To treat relapsing forms of multiple sclerosis FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 To treat relapsing forms of multiple sclerosis drug. 1 FDA approval recorded, most recently Briumvi (ublituximab-xiiy) on December 28, 2022.

Drugs

DrugSponsorModalityDesignations
Briumvi (ublituximab-xiiy)TGTXbiologic—

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
December 28, 2022Briumvi (ublituximab-xiiy)TGTXFDA approvalTo treat relapsing forms of multiple sclerosisApprovedFDA Novel Drug Approvals

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What To treat relapsing forms of multiple sclerosis drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.